Corbus Pharmaceuticals has received FDA alignment on its proposed registrational study design for CRB-701, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, in the treatment of head and neck squamous cell carcinoma (HNSCC) and cervical cancer. This development allows Corbus to advance towards potential accelerated approval, with a focus on objective response rate (ORR) as the primary endpoint in both cancers. The company plans to initiate a randomized controlled study comparing CRB-701 to physician’s choice chemotherapy, with the possibility of full approval contingent on overall survival (OS) benefits.

The significance of this alignment lies in the therapeutic potential of CRB-701, which is designed to address unmet medical needs in oncology. The ADC employs a site-specific, cleavable linker and a homogeneous drug-antibody ratio of 2, using MMAE as the payload. The FDA has granted Fast Track designations for CRB-701 in both HNSCC and cervical cancer, underscoring its promise in treating these malignancies. Updated clinical data from the Phase 1/2 study, including efficacy and safety results, will be presented at the upcoming ASCO 2026 Annual Meeting, further elucidating the drug’s potential.

The takeaway from this advancement is the shift in Corbus’s development strategy, moving from proof of concept to late-stage registrational studies. This transition not only positions CRB-701 for potential regulatory submission but also emphasizes the importance of ongoing FDA interactions to finalize study protocols. As Corbus prepares for this critical phase, the company anticipates bolstering its leadership team to navigate the complexities of late-stage clinical development, which could significantly impact timelines for bringing innovative therapies to market in oncology.

Source: globenewswire.com